{Reference Type}: Journal Article
{Title}: Pilonidal sinus disease carcinoma: Survival and recurrence analysis.
{Author}: Safadi MF;Degiannis K;Doll D;
{Journal}: J Surg Oncol
{Volume}: 128
{Issue}: 4
{Year}: 2023 Sep 17
{Factor}: 2.885
{DOI}: 10.1002/jso.27319
{Abstract}: <B>BACKGROUND: </B>The study aims to determine the survival and recurrence rates of pilonidal sinus disease (PSD) carcinoma.<BR><B>METHODS: </B>The data were collected retrospectively by searching the worldwide literature for all reports of carcinoma developing on the background of PSD. The results were presented using Kaplan-Meier curves.<BR><B>RESULTS: </B>Between 1900 and 2022, 140 cases of PSD carcinoma were published in 103 papers, with follow-up data available in 111 cases. Squamous cell carcinoma constituted 94.6% of the cases (n = 105). The disease-specific survival rate was 61.7% for 3 years, 59.8% for 5 years, and 53.2% for 10 years. There was a significant survival difference between stages: 80.0% in stages I and II, 70.8% in stage III, and 47.8% in stage IV (p = 0.01). The 5-year survival in G1-tumors was better than G2 and G3-tumors at 70.5% and 32.0%, respectively (p = 0.002). Recurrence occurred in 46.6% of the patients. The time-to-recurrence in patients treated with curative intention averaged 15.1 months (1-132 months). Local, regional, and distant recurrence was observed in 75.6%, 33.3%, and 28.9% of the recurrent tumors, respectively.<BR><B>CONCLUSIONS: </B>Pilonidal sinus carcinoma has a worse prognosis than primary cutaneous squamous cell carcinoma. Poor prognostic factors include advanced-stage disease and poor differentiation.